Merck reorganized its human health operations into two separate businesses, creating a standalone oncology unit and a second division for specialty, pharma and infectious diseases. The change accompanies a leadership shuffle that names Jannie Oosthuizen to lead the oncology unit. The move is explicitly positioned as a response to the impending loss of exclusivity for Keytruda in 2028 and aims to sharpen focus on oncology launches and commercialization while isolating non‑oncology growth drivers like vaccines and cardiometabolic medicines.